Australia Science

NASA says there's an 80% chance the Artemis II mission will launch on Wednesday from Cape Canaveral in Florida. Bloomberg's Loren Grush is there with more on what to watch for.

President Donald Trump appointed tech industry leaders including Mark Zuckerberg of Meta, venture capitalist Marc Andreessen, and Nvidia CEO Jensen Huang to a new presidential technology council that will focus on artificial intelligence policy and other science-related issues. David Sacks, Craft Ventures partner and co-chair of the President's Council of Advisors on Science and Technology, joins Ed Ludlow on "Bloomberg Tech."

NASA administrator Jared Isaacman says he's confident that the agency will have the cash it needs to build a new moon base President Donald Trump has asked for. He says some resources have to be moved around. He speaks on "Bloomberg Tech."

NASA says it's planning to launch the Artemis II Space Launch System rocket as soon as April 1. The massive rocket would take four astronauts around the moon. Lori Glaze, NASA's acting associate administrator of exploration systems development, spoke to reporters on Thursday.

Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, previews Nvidia earnings. Nvidia Corp.'s earnings report on Wednesday afternoon comes at a critical time for the US stock market with investors increasingly nervous about the outlook for artificial intelligence. While most Wall Street pros are anticipating strong results from the chipmaker amid ballooning spending on computing infrastructure, there is less certainty about how its shares and others will respond at a time when fears about AI disruption and the staying power of heavy investments are dominating the tape. "Even if they have tremendous numbers, we know the markets are really fickle," said Ken Mahoney, president of Mahoney Asset Management.

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly's tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest."

Aumake (ASX:AUK) formalised a strategic four-year exclusive global distribution agreement with EZZ Life Sciences (ASX:EZZ).

Vitrafy Life Sciences (ASX:VFY) has entered a 12-month exclusive collaboration and development agreement with global animal reproduction leader IMV Technologies, SA.

Anatara Lifesciences (ASX:ANR), a developer of evidence-based health products, has provided an update on its Anti-Obesity Project.